Hovione buys Pfizer’s Loughbeg API Facility

Ivan Villax Traineeship Program

Hovione’s sales grow 11%

Sales reach USD 103.7 million for the fiscal year ended March 31st 2008.

Hovione buys drug manufacturing facility in China

FDA inspects Hovione’s Technology Transfer Center in New Jersey

Hovione in New Jersey awarded VPP Star status by OSHA

Hovione’s sales grow 16%

Hovione expands its range of services in Particle Design technology

To address a significant market interest in Advanced APIs (aAPI®), Hovione has increased its range of services and multi-scale facilities in cGMP Spray Drying

Hovione Group sales grow 8% for fiscal year 2004/05

Hovione announces that the consolidated sales volume for the fiscal year ended 31st March 2005 amounted to US$81.4 million, representing a growth of 8% over the previous year.

Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance

Allos Therapeutics, Inc. and Hovione announced today that they have entered into a long-term manufacturing agreement for the supply of EFAPROXYN bulk drug substance, efaproxiral sodium.